louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02724982: Body Image Satisfaction In Relation To Body Mass Index And Self- Esteem Among Chinese Female Students
Official title: Body Image Satisfaction In Relation To Body Mass Index And Self- Esteem Among Chinese Female Students: A Cross Sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Self esteem
Body mass index
Lead sponsor: Universiti Tunku Abdul Rahman
Sponsor class: OTHER
First posted: 2016-03-31
Enrollment: 176
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chinese female university students in UTAR, Sungai Long campus, Malaysia

Brief summary: Body image satisfaction and self- esteem level are important to be known among students in order to intervene in a correct time. Body dissatisfaction is one of the factors leading to negative self-perception, low mood, depression, and eating disorders. This may be detrimental to students in their academic performance. However, the correlations of body image satisfaction towards body mass index and self- esteem among university female students are still unclear in Malaysia. Thus, the purpose of this study is to determine its relationships among Chinese female students. university female participants will be included with convenience sampling method. Participants will completed Ronsenberg Self- Esteem Scale and 8 items version of Body Shape Questionnaire. These 2 scales used to measure level of self- esteem and body image satisfaction. Body mass index will be calculated from self- reported height and weight. The data will be analysed by using descriptive and correlation methods.


Eligibility criteria: Inclusion Criteria:

* Female and Chinese students
* Age more or equal than 20 years ( ≥20 )
* UTAR students

Exclusion Criteria:

* Male and non-Chinese students
* Age less than 20 ( \<20 )
* Non- UTAR students

Primary outcomes:
measure: Ronsenberg Self- Esteem Scale
timeFrame: Baseline
measure: body image satisfaction questionnaire
timeFrame: Baseline
measure: Body mass index
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Kajang
country: Malaysia
facility: Universiti Tunku Abdul Rahman
state: Selangor
Study officials:
References:
Clinical trial NCT07000682: The Clinical Study on the Treatment of SSc With UTAA91 Injection.
Official title: Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: EARLY_PHASE1
Conditions: Systemic Sclerosis (SSc)
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: After signing the informed consent form, eligible subjects will be infused with UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, safety, etc.
Primary purpose: TREATMENT

Brief summary: This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.


Eligibility criteria: Inclusion Criteria:

* Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.

Expected survival time of ≥3 months. Refractory moderate - to - severe active systemic sclerosis that has failed standard treatment or lacks effective therapeutic options.

Meets the requirements for liver and kidney function, as well as cardiopulmonary function.

Free from severe psychiatric disorders. Able to understand the trial and has signed the informed consent form.

Exclusion Criteria:

* A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening.

Positive results in virology/syphilis tests. Severe cardiac diseases or unstable systemic diseases. Presence of active or uncontrollable infections requiring systemic treatment, or evidence of central nervous system invasion.

Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.

Subjects who have received CAR - T therapy or other gene - modified cell therapies prior to screening.

Subjects who participated in other clinical studies within 1 month prior to screening.

Other conditions deemed unsuitable for enrollment by the investigator.

Primary outcomes:
measure: Adverse events
timeFrame: About 1 year
Secondary outcomes:
measure: Cmax
timeFrame: About 1 year
measure: Tmax
timeFrame: About 1 year
measure: Disease remission rate
timeFrame: About 3 months
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT04420182: COVID-19 Virtual Care at Home
Official title: COVID-19 Virtual Care at Home
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Covid-19
Keywords: COVID-19
SARS-CoV-2
VIRTUES
Virtual Care Management
Virtual Care
Patient Satisfaction
Anxiety
Emergency Visits
Oxygen Saturation
Quality of Life
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
Collaborators: name: Cardiac Arrhythmia Network of Canada
First posted: 2020-06-09
Enrollment: 817
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Prospective non-randomized cohort study
Primary purpose: TREATMENT

Brief summary: This multicentre prospective cohort trial is designed to demonstrate effectiveness and efficiency of a virtual care model for the management of COVID-19 patients isolating at home. The investigators have reoriented existing technology and networks for this research project. The investigators are amplifying our existing virtual care platform VIRTUES, combining it with home monitoring of COVID-19 patients, to provide real-time evidence, harmonize data collection, and share data provincially to mitigate the impact of the rapid spread of the virus. The study will facilitate early detection of complications associated with the disease, treatment and management of COVID-19 patients at home. The research will be conducted provincially in Ontario.

This initiative will provide evidence to inform clinical and health system management and public health response to COVID-19 patients isolating at home.


Eligibility criteria: Inclusion Criteria:

* All COVID-19 positive patients of age 18 or above
* Participant must communicate in English or French language
* An email address and account

Exclusion Criteria:

* Unable or unwilling to provide informed consent

Primary outcomes:
measure: 14 Day Patient Satisfaction Questionnaire
timeFrame: 14 days
Secondary outcomes:
measure: Emergency Department Visits
timeFrame: 14 days
measure: 14 Day EQ-5D-5L Scores
timeFrame: 14 days
Other outcomes:
Locations:
city: Kitchener
country: Canada
facility: St. Mary's General Hospital
state: Ontario
city: London
country: Canada
facility: London Health Sciences Centre
state: Ontario
city: Ottawa
country: Canada
facility: Ottawa Heart Research Institute
state: Ontario
city: St. Catharines
country: Canada
facility: Niagara Health
state: Ontario
city: Toronto
country: Canada
facility: St. Joseph's Health Centre
state: Ontario
Study officials:
References:
Clinical trial NCT06288282: Behavioral and Cognitive Predictors of Persistent Pain and Opioid Misuse in Chronic Pain
Official title: Behavioral and Cognitive Predictors of Persistent Pain and Opioid Misuse in Chronic Pain
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Back Pain
Lead sponsor: Icahn School of Medicine at Mount Sinai
Sponsor class: OTHER
First posted: 2024-03-01
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: chronic back pain

Brief summary: Chronic lower back pain (CLBP) affects approximately 20% of the global population. The study objective is to determine if impulsivity, inhibitory control, drug choice, and/or cognitive distortions predict opioid misuse and disability in patients with chronic pain. This is a prospective consented cross-sectional study characterizing behavioral and cognitive phenotypes using both patient-reported survey measures and cognitive testing. Outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and risk for opioid misuse (Primary outcomes: COMM scores, SOAPPR scores). Secondary outcomes is BPI measurement. A Certificate of Confidentiality will provide additional protections for participants.


Eligibility criteria: Inclusion Criteria:

* With diagnoses related to chronic lower back pain
* Age above 18yrs
* Non pregnant

Exclusion Criteria:

* Cancer pain

Primary outcomes:
measure: Screener and Opioid Assessment for patients with pain revised (SOAPPR)
timeFrame: within 12 months
measure: Current Opioid misuse measure (COMM) surveys
timeFrame: within 12 months
Secondary outcomes:
measure: Pain Intensity with Brief Pain inventory (BPI)
timeFrame: within 12 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai Pain management centers
state: New York
Study officials:
affiliation: Icahn School of Medicine at Mount Sinai
name: Chinwe Nwaneshiudu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06630182: Evaluation of the Impact of Psychological Profile on Diabetic Foot Wound Healing. Prospective, Monocentric Study
Official title: Evaluation of the Impact of Psychological Profile on Diabetic Foot Wound Healing. Prospective, Monocentric Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Type 2 Diabetes
Foot Wound
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2024-10-08
Enrollment: 308
Sex: ALL
Minimum age (years): 18
Maximum age (years): 18
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with type 2 diabetes referred for management of a new diabetic foot ulcer

Brief summary: Foot wounds in patients with diabetes are one of the most frequent complications associated with diabetes. Despite the progress made in its management in recent years, the risk of amputation remains high in cases of diabetic foot wounds.

Several studies have highlighted the value of analyzing the psychological profile A or B, defined by self-questionnaire using Bortner's method. The A personality profile is characterized by hyperactivity, combativeness and exaggerated ambition, while the B profile is characterized by less sensitivity to stress and reduced combativeness.

Type A personality profile is associated with reduced cardiovascular mortality in type 1 diabetes. Type B personality profiles have also been shown to be associated with inflammation in both type 1 and type 2 diabetes.

Our group showed that patients with diabetes and a foot wound were more likely to have a type B psychological profile than patients with diabetes and no foot wound.

However, to our knowledge, it has never been determined whether the psychosomatic profile type A or B assessed by the Bortner self-questionnaire influenced wound healing and the risk of amputation.

The aim of this study is to determine whether type A or B psychosomatic profile influences wound healing in diabetic feet.

This study will be carried out in the endocrinology, diabetology and nutrition department of the Dijon Bourgogne University Hospital. 308 patients will be included in the study.


Eligibility criteria: Inclusion Criteria:

* Person who has given his non-opposition
* Person over 18 years of age
* Person with type 2 diabetes
* Person referred for management of a new diabetic foot wound

Exclusion Criteria:

* Person subject to a legal protection measure (curatorship, guardianship)
* Person subject to a legal protection measure
* Pregnant women, women in labour or breastfeeding mothers
* An adult who is incapable or unable to give consent
* Minors
* Person unable to complete self-questionnaires

Primary outcomes:
measure: Bortner self-questionnaire score
timeFrame: At 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU Dijon Bourgogne
Study officials:
References:
Clinical trial NCT00725582: Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
Official title: The Effects of IMA-026 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects With Mild Atopic Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Asthma
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2008-07-30
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8.


Eligibility criteria: Inclusion Criteria:

1. Healthy men and women 18 to 60 yrs with mild allergic asthma
2. only asthma med is short-acting bronchodilator used not more than twice weekly
3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Exclusion Criteria:

1. Upper respiratory infection or asthma exacerbation with 4 weeks of screening
2. Serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of test article administration
3. Positive radiographic findings indicative of respiratory disease other than asthma

Primary outcomes:
measure: Comparison of the maximum change in FEV1 from baseline for the LAR between IMA-026 and placebo
timeFrame: 11 weeks
Secondary outcomes:
measure: Treatment comparison of the hour 3 and hour 7 FEV1 AUC for the LAR; various comparisons of the methacholine PC20
timeFrame: 11 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O'Byrne PM. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1007-14. doi: 10.1164/rccm.201008-1210OC. Epub 2010 Nov 5.
Clinical trial NCT03780582: Evaluation of Use of Diagnostic AI for Lung Cancer in Practice
Official title: Evaluation of Use of Diagnostic AI for Lung Cancer in Practice
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lung Cancer
Lead sponsor: Ensemble Group Holdings, LLC
Sponsor class: INDUSTRY
First posted: 2018-12-19
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This study investigates ways of improving radiologists performance of the classification of CT-scans as cancerous or non-cancerous. Participants interact with an AI to classify CT-scans under three different conditions.

Detailed description: The three conditions are as follows: "probabilistic classification", where the radiologist diagnoses scans using an AI cancer likelihood score; "classification plus detection", where the radiologist see detecting lung nodules in addition to the AI's probabilistic classification score before making her own examination of the CT-scan; and "classification with delayed detection", where the radiologist identifies regions of interest independently of the AI and then sees the AI's detected ROIs.

Eligibility criteria: Inclusion Criteria:

* The participant performs radiology screenings professionally

Exclusion Criteria:

-

Primary outcomes:
measure: Classification accuracy
timeFrame: up to 4 months after initiation of evaluation of the test set
Secondary outcomes:
measure: detection concordance
timeFrame: up to 4 months after initiation of evaluation of the test set
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: University of Hong Kong
Study officials:
References:
Clinical trial NCT06693882: Electrical Stimulation of the Optic Nerve in Patients With Glaucoma.
Official title: Electrical Stimulation of the Optic Nerve in Patients With Glaucoma : Prospective Analysis of Perimetric Data up to 12 Months After Neuromodulatory Treatment.
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Glaucoma
Lead sponsor: Glaucoma Center of San Francisco
Sponsor class: OTHER
First posted: 2024-11-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Prospective analysis
Primary purpose: TREATMENT

Brief summary: The goal of this observational study is to evaluate electrical stimulation of the optic nerve with the Eyetronic Nextwave System device as a possible treatment for glaucoma.

The main question it aims to answer is:

Could this therapy be an option to counteract the loss of visual field seen in glaucoma and thus delay the progression of the disease?

Participants will have approximately 14-18 study visits during 12 months including 10 visits for the electrical stimulation treatment. The treatment involves electrically stimulating the optic nerve by an external approach via the facial skin.

Detailed description: 1. During the study visits participants will have: general eye examination (visual acuity check, examination of the front and back of the eye, eye pressure measurement, pupil dilation), Visual field (VF) testing, Imaging the optic nerve with Optical Coherence Tomography (OCT), Optic nerve photos.
2. The treatment will include ten sessions during 2 weeks on an outpatient basis in a quiet and dimly lit room with the patient comfortably seated or lying down in a reclining chair. Each treatment session will last approximately 60 minutes including the time to determine the treatment settings.

Eligibility criteria: Inclusion Criteria:

* Subjects 18 years or older who have glaucoma
* Humphrey visual field mean deviation (MD) values between - 6 dB and -20 dB

Exclusion Criteria:

* Age \< 18 years
* Implanted electronic devices
* Metallic artifacts in the head (except dentures)
* Migraine
* Epilepsy
* Brain tumor
* Pregnancy
* Breastfeeding patients
* Uncontrolled intraocular pressure (IOP)
* IOP lowering medication started less than six months before enrollment
* Any intraocular surgery less than 6 months before enrollment
* Arterial hypertension without appropriate treatment
* Acute retinal hemorrhage

Primary outcomes:
measure: Change in visual field mean deviation (MD) from baseline to post-treatment
timeFrame: 12 months
Secondary outcomes:
measure: Change in retinal nerve fiber layer (RNFL) thickness from baseline to post-treatment
timeFrame: 12 months
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Glaucoma Center of San Francisco
state: California
Study officials:
References:
Clinical trial NCT04512482: Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse
Official title: A Visual Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse in Orthodontic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dental Plaque
Dental Caries
Keywords: proteolytic enzyme
plaque removal
oral hygiene
orthodontic treatment
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: Water Pik, Inc.
name: Delta Dental Foundation
First posted: 2020-08-13
Enrollment: 46
Sex: ALL
Minimum age (years): 10
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Enrolled subjects undergoing orthodontic treatment with fixed appliances will be randomized to receive either the Bromelain rinse or Placebo first and then will be crossed over to receive the opposite intervention. The study will consist of two treatment period (1 day) separated by a washout period of 1 week.
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to investigate the impact of a bromelain pre-rinse adjunct on oral plaque removal in orthodontic subjects. The study's null hypothesis states that there is no statistically significant difference in visual plaque scores among orthodontic subjects with or without proteolytic enzyme rinse aid.

Detailed description: Bromelain, a naturally occurring cysteine protease, from pineapple stalks, is used in food and medical industries and listed on the FDA's "Generally Recognized As Safe" (GRAS) list. In vitro bromelain study demonstrated antibacterial effect on oral pathogens. Bromelain was found to prevent biofilm formation by interfering with bacteria-bacteria adhesion and/or adhesion to enamel surface. Clinical trials with toothpaste containing bromelain demonstrated improved plaque and gingivitis scores and extrinsic enamel stain removal capabilities. The impact of bromelain application prior to traditional mechanisms of plaque removal have not been clearly evaluated.

Eligibility criteria: Inclusion Criteria:

* male or female
* 10 to 25 years of age
* willing to consent to participation
* able to follow study instructions
* in active orthodontic treatment with fixed orthodontic appliances

Exclusion Criteria:

* unwilling/unable to follow study instructions
* documented/suspected pineapple allergy
* proteolytic enzyme allergy
* food dye allergy
* smoker

Primary outcomes:
measure: Composite Plaque Score
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University School of Dentistry
state: Indiana
Study officials:
affiliation: Indiana University
name: Kelton Stewart, DDS, MS
role: PRINCIPAL_INVESTIGATOR
References: